Physician profile
Stuart J Benson
NPI 1629028584
$23,969.41
in general payments reported to CMS, 2019-2025
49 companies · $4,508 in 2025
The $4,508 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $927 · 2020: $4,806 · 2021: $2,462 · 2022: $927 · 2023: $6,830 · 2024: $3,510 · 2025: $4,508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $3,647.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,200.00 |
| Food and Beverage | $3,647.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $12,009.49 | 2019-2025 | Otezla, Otezla, Evenity |
| Allergan, INC. | $4,854.28 | 2019-2021 | |
| Novo Nordisk INC | $1,109.45 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $813.07 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Astellas Pharma US INC | $399.46 | 2019-2023 | Veozah |
| Lilly USA, LLC | $373.44 | 2020-2025 | Mounjaro, Emgality, Jardiance |
| Sanofi-Aventis U.S. LLC | $330.03 | 2019-2023 | |
| Dexcom, INC. | $311.78 | 2021-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $307.74 | 2020-2021 | |
| Glaxosmithkline, LLC. | $304.58 | 2020-2022 | |
| Abbvie INC. | $248.84 | 2021-2024 | Qulipta, Ubrelvy |
| Abbott Laboratories | $247.70 | 2019-2025 | Freestyle Libre 3, Freestyle Libre, Freestyle Libre 2 |
| Idorsia Pharmaceuticals US INC | $240.99 | 2023-2024 | Quviviq |
| Pfizer INC. | $234.57 | 2019-2025 | |
| Eisai INC. | $232.17 | 2021-2024 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Benson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.